Molecular biology of exocrine pancreatic cancer.
Exocrine pancreatic cancer is one of the neoplasias with a worse prognosis, with conventional treatments having little impact on disease outcome. Research and genomic high-throughput technology is continuously expanding our knowledge of pancreas cancer biology. Characterization of genetic and epigenetic alterations in pancreatic tumors has allowed a better understanding of the progression model of the disease at the molecular level. The development of new therapeutic approaches with target- oriented agents is been tested in the preclinical and clinical settings. This review updates the current available data on pancreatic cancer molecular biology.
Soto
J L
JL
Laboratorio de Oncología Molecular, Hospital General Universitario de Elche e Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Elche, Spain.
Barbera
V M
VM
Saceda
M
M
Carrato
A
A
D021441:Carcinoma, Pancreatic Ductal / Q000235:genetics; D002869:Chromosome Aberrations; D018450:Disease Progression; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor; D019942:Genes, p16; D016158:Genes, p53; D011905:Genes, ras; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics; D009386:Neoplastic Syndromes, Hereditary / Q000235:genetics; D009857:Oncogenes; D010190:Pancreatic Neoplasms / Q000235:genetics*; D011379:Prognosis
D009363:Neoplasm Proteins